Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.72 BRL | -0.56% |
|
-.--% | -10.95% |
06-20 | Needham Adjusts Price Target on Jazz Pharmaceuticals to $210 From $222, Maintains Buy Rating | MT |
06-20 | Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday | MT |
Sales 2024 * | 4.05B 22.68B 5.54B | Sales 2025 * | 4.37B 24.44B 5.97B | Capitalization | 6.73B 37.65B 9.21B |
---|---|---|---|---|---|
Net income 2024 * | 432M 2.42B 591M | Net income 2025 * | 598M 3.35B 818M | EV / Sales 2024 * | 2.53 x |
Net Debt 2024 * | 3.54B 19.78B 4.84B | Net Debt 2025 * | 2.21B 12.35B 3.02B | EV / Sales 2025 * | 2.05 x |
P/E ratio 2024 * |
18.1
x | P/E ratio 2025 * |
12.5
x | Employees | 2,800 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.22% |
Latest transcript on Jazz Pharmaceuticals plc
1 day | -0.56% | ||
3 months | -7.19% | ||
6 months | -10.95% | ||
Current year | -10.95% |
![Extreme 38.72](/images/extremecours_fleche.png)
![Extreme 38.72](/images/extremecours_fleche.png)
![Extreme 38.72](/images/extremecours_fleche.png)
![Extreme 38.72](/images/extremecours_fleche.png)
![Extreme 38.72](/images/extremecours_fleche.png)
Managers | Title | Age | Since |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 03-02-28 |
Renée Galá
PSD | President | 52 | 20-03-15 |
Robert Iannone
CTO | Chief Tech/Sci/R&D Officer | 57 | 19-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 03-02-28 |
Norbert Riedel
BRD | Director/Board Member | 66 | 13-05-12 |
Patrick Enright
BRD | Director/Board Member | 62 | 08-12-31 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.32% | 815B | |
+44.05% | 641B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+2.04% | 224B | |
+13.31% | 218B | |
+8.48% | 168B |
- Stock Market
- Equities
- JAZZ Stock
- J2AZ34 Stock